Trial Profile
Open-label Phase 2 Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Therapeutic Use
- 03 Jun 2010 New trial record